Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...
Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided ...
Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers ...
The central role of Epstein-Barr virus in causing multiple sclerosis is examined to understand how it triggers the disease and presents new opportunities for treatment “Evidence is mounting that you ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback